Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-s

Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RA

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) wi

Company received written feedback from the U.S. Food and Drug Administration ("FDA") regardi

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 0

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-

Designation supports development in an estimated $1 billion market where there are no FDA-approved t

REO 033 builds upon the previously reported REO 022 study, which more than doubled historical standa

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-ide

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's

Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Prev

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” o

Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specif

Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising dur

2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Mo

Company to leverage strong durability and survival data in second-line and later metastatic squamous

Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer,

Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) and Erasca (NASDAQ: ERAS - Get Free Report) are

SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics”

Oncolytics Biotech Inc. (NASDAQ: ONCY - Get Free Report) has been given an average rating of "Modera

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics”

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary

Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation 

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by

Oncolytics Biotech (NASDAQ: ONCY - Get Free Report) is expected to release its Q4 2025 results befor

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earning

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report q

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q

Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the comp

Companies Reporting Before The Bell • CNH Industrial (NYSE:CNHI) is estimated to report quarterly e

Companies Reporting Before The Bell • Hibbett (NASDAQ:HIBB) is projected to report quarterly earnin

Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quar

Upgrades

  Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarte

  On Tuesday, 951 companies hit new 52-week lows.

  During Monday's trading, 1214 companies set new 52-week lows.